Indian Biosimilars and Vaccines at Crossroads-Replicating the Success of Pharmagenerics.

ABSTRACT:

Background

The global pharma sector is fast shifting from generics to biologics and biosimilars with the first approval in Europe in 2006 followed by US approval in 2015. In the form of Hepatitis B vaccine, India saw its first recombinant biologics approval in 2000. Around 20% of generic medications and 62% of vaccines are now supplied by the Indian pharmaceutical industry. It is this good position in biologics and biosimilars production that could potentially improve healthcare via decreased treatment cost. India has witnessed large investments in biosimilars over the years. Numerous India-bred new players, e.g., Enzene Biosciences Ltd., are keen on biosimilars and have joined the race alongside the emerging giants, e.g., Biocon and Dr. Reddy's. A very positive sign was the remark

SUBMITTER: Panda S 

PROVIDER: S-EPMC9865573 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature